American Society of Clinical Oncology Annual Meeting 2025

The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting took place from May 30 to June 3 in Chicago, Illinois, under the theme “Driving Knowledge to Action: Building a Better Future”.
Here are some key highlights:

Over 5,400 presentations covered cutting-edge research, clinical trials, and treatment innovations across a wide range of cancers.
Breast, lung, ovarian, and colorectal cancers were among the most featured tumor types.
AstraZeneca and Daiichi Sankyo presented promising results from the DESTINY-Breast09 study, suggesting a potential new standard of care for HER2-positive metastatic breast cancer.
Gilead and Merck & Co made headlines with their TROP-2–targeted therapy Trodelvy combined with Keytruda, showing strong results in triple-negative breast cancer.
Amgen’s Imdelltra showed significant benefit in small cell lung cancer, a notoriously tough-to-treat disease.
In ovarian cancer, the ROSELLA trial and OVATION-2 study offered encouraging data for patients with resistant or advanced disease

The target audience for the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting is impressively broad, reflecting the multidisciplinary nature of cancer care. It includes:

Medical, surgical, and radiation oncologists
Hematologists, pathologists, and radiologists
Primary care physicians and internal medicine specialists
Gynecologic, thoracic, colorectal, and urologic surgeons
Pulmonologists, dermatologists, and oral surgeons
Oncology nurse practitioners, nurses, and physician assistants
Residents, fellows, and medical students
Allied health professionals involved in oncology care and research

The meeting is designed to foster collaboration across specialties, highlight the latest in clinical and translational research, and support continuing education for professionals at all stages of their careers
 
+ Topics:
*Note: Agenda